Welcome! Log into your account
Forgot your password? Get help
Recover your password
A password will be e-mailed to you.
Tag: Johnson & Johnson
Court Ordered Johnson & Johnson to Pay $8bn
Johnson & Johnson must pay $8 billion in punitive damages to a man who previously won $680,000 over his claims that it failed to warn that young men using its antipsychotic drug Risperdal could gr...
Johnson & Johnson Dedicated $500m to Eliminate HIV and Tuberculosis by 2030
Johnson & Johnson announced that it has committed to ensuring more than $500 million is dedicated to world class research & development and delivery programs over the next four years to accele...
J&J Announced Agreement with Ohio Counties Ahead of Upcoming Opioid Trial
Johnson & Johnson and its Janssen Pharmaceutical Companies announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties’ claims with no admissio...
J&J Stelara Approved in EU for Ulcerative Colitis
Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared...
J&J Announced Launch of Consortium to Discover and Develop New TB Antibiotics
As part of the Company’s 10-year initiative to drive progress against tuberculosis (TB), Johnson & Johnson announced that it has launched an international research consortium to discover and devel...
U.S. Justice Department Pursue Investigation over Cancer Risk in J&J’s Powder
The U.S. Justice Department is pursuing a criminal investigation into whether Johnson & Johnson lied to the public about the possible cancer risks of its talcum powder, people with knowledge of th...
Celsius and Janssen in Collaboration
Celsius Therapeutics announced a collaboration with Janssen Biotech. Under the terms of the agreement, Celsius will apply its proprietary single-cell genomics and machine learning platform to identify...
Johnson & Johnson Announced Results from the Phase 3 Study of XARELTO®
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged birth to 17 years) treated with XARELTO® (rivar...
J&J’s INVOKANA Significantly Reduced Major Cardiovascular Events and Kidney Failure
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of a new subgroup analysis from the landmark phase 3 CREDENCE study, showing INVOKANA® (canagliflozin) significantly red...
J&J Published Data from Phase 3 DARZALEX® Study
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the publication of data from the randomized, open-label Phase 3 MAIA (MMY3008) study that showed DARZALEX® (daratumumab) plus le...
J&J Used Underhanded Tactics to Fend Off Generics
Johnson & Johnson’s blockbuster cancer med Zytiga only recently lost its shield against generic competition, and according to a new lawsuit, that’s because J&J used underhanded tactics to ke...
J&J Presented Early Results from First-In-Human Study of Monarch™ Platform
Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies, announced early positive results from an ongoing study designed to evaluate the safety and feasibility of the Monarch Platf...
Janssen Submitted Application for ERLEADA Approval
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approv...
Xarelto’s Sales Drop as Competition Pile Up
After a rough year for Bayer and Johnson & Johnson's anticoagulant Xarelto, the companies hoped the competition would take it easy in 2019. Pfizer and Bristol-Myers Squibb's Eliquis had other plan...
Johnson & Johnson Beats Estimates on Pharma Strength, Raises Sales Forecast
Johnson & Johnson beat quarterly profit estimates on Tuesday and raised its adjusted sales growth forecast for the year, driven by demand for its treatment for psoriasis and Crohn’s disease and ca...
J&J Completes Acquisition of Auris Health
Johnson & Johnson announced that Ethicon, Inc., has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, i...
Page 1 of 3
Pharmasyntez Group of Companies
Rafarma – a full cycle pharmaceutical enterprise
Binnopharm – full-cycle biopharmaceutical faciliti...
Pharmacor Production Ltd.
R-Pharm – Russian High-Tech Pharmaceutical Enterprise
EXCELLENCE IN OLEOCHEMICAL EXCIPIENTS AND APIs
Top 30 pharmaceutical contract manufacturing organisations
GMP Inspection practice: a case for global benchmarking, con...
EAEU may allow to register empty primary packages as medical...
Head of SID & GP Dispeled Myths about Russian Medicines...
Ilumina Pharma Announced Launch of New DNA Decoded Resources...
PRAC Recommended Limiting Use of High-Strength Creams to 4 W...
Subscribe to Newsletter!
© GMP news